Eloxx Pharmaceuticals To Present at the 38th Annual Canaccord Genuity Growth Conference
July 18, 2018 07:30 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals To Report Second Quarter 2018 Financial Results On August 7, 2018 and Host Webcast and Conference Call
July 17, 2018 07:30 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Expands Leadership Team with Two Global Pharmaceutical Executives to Accelerate Growth
June 25, 2018 16:20 ET
|
Eloxx Pharmaceuticals
Dr. Greg Williams appointed Chief Operating Officer David P. Snow appointed Chief Business Officer Eloxx added to the Russell 2000® Index effective June 25, 2018 WALTHAM, Mass., June 25, 2018 ...
Eloxx Appoints Global Pharmaceutical Leader, Neil Belloff, Executive Vice President, General Counsel and Corporate Secretary
June 18, 2018 07:30 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”) (Nasdaq:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the 41st European Cystic Fibrosis Conference (ECFS)
June 08, 2018 11:00 ET
|
Eloxx Pharmaceuticals
ELX-02 demonstrated dose-dependent rescue of CFTR function in human bronchial epithelial cells (HBEs) and organoids from patients carrying at least one nonsense CFTR mutation Eloxx expects to...
Eloxx Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results and Provides Business Update
May 10, 2018 16:01 ET
|
Eloxx Pharmaceuticals
Company on track to initiate Phase 2 clinical trials for investigational drug ELX-02 in cystic fibrosis and cystinosis in 2018 and sufficiently funded to top line data Formation of Scientific...
Eloxx Pharmaceuticals To Report First Quarter 2018 Financial Results On May 10, 2018 and Host Webcast and Conference Call
May 01, 2018 13:27 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”), (Nasdaq:ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Eloxx Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
April 30, 2018 16:01 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”) (Nasdaq:ELOX) today announced the completion of its previously announced underwritten public offering of...
Eloxx Pharmaceuticals Announces FDA Grant of Orphan-Drug Designation for Investigational Drug ELX-02 for Treatment of Cystinosis
April 27, 2018 12:41 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., April 27, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”), (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of...
Eloxx Pharmaceuticals Announces Uplisting to Nasdaq and Pricing of $50 Million Public Offering of Common Stock
April 25, 2018 18:22 ET
|
Eloxx Pharmaceuticals
WALTHAM, Mass., April 25, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (“Eloxx”) (Nasdaq:ELOX) today announced the pricing of an underwritten public offering of 5,130,000 shares of its...